182 related articles for article (PubMed ID: 26503109)
21. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
22. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
23. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
24. Effects of Androgen Deprivation Therapy on Extraocular Muscles, Retrobulbar Orbital Fat, and the Optic Nerve in Patients with Prostate Cancer.
Sonmez HK; Sonmez G; Dogan S; Horozoglu F; Demirtas A; Evereklioglu C
Ophthalmic Res; 2023; 66(1):272-280. PubMed ID: 36228576
[TBL] [Abstract][Full Text] [Related]
25. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.
Derweesh IH; Diblasio CJ; Kincade MC; Malcolm JB; Lamar KD; Patterson AL; Kitabchi AE; Wake RW
BJU Int; 2007 Nov; 100(5):1060-5. PubMed ID: 17868420
[TBL] [Abstract][Full Text] [Related]
26. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
Wong CHM; Xu N; Lim J; Feng KK; Chan WKW; Chan MTY; Leung SC; Chen DN; Lin YZ; Chiu PKF; Yee CH; Teoh JYC; Huang CY; Yeoh WS; Ong TA; Wei Y; Ng CF
Prostate; 2023 Jun; 83(8):801-808. PubMed ID: 36938957
[TBL] [Abstract][Full Text] [Related]
27. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.
Sun L; Parikh RB; Hubbard RA; Cashy J; Takvorian SU; Vaughn DJ; Robinson KW; Narayan V; Ky B
JAMA Netw Open; 2021 Feb; 4(2):e210070. PubMed ID: 33625512
[TBL] [Abstract][Full Text] [Related]
28. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Stein MN; Hussain M; Stadler WM; Liu G; Tereshchenko IV; Goodin S; Jeyamohan C; Kaufman HL; Mehnert J; DiPaola RS
Clin Genitourin Cancer; 2016 Feb; 14(1):22-7. PubMed ID: 26476589
[TBL] [Abstract][Full Text] [Related]
29. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
30. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
Ziaran S; Goncalves FM; Breza J
World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
[TBL] [Abstract][Full Text] [Related]
31. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
32. The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation.
Watanabe D; Kimura T; Yamashita A; Minowa T; Miura K; Mizushima A
Aging Male; 2020 Dec; 23(5):1158-1164. PubMed ID: 31959023
[TBL] [Abstract][Full Text] [Related]
33. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
34. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
35. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
36. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.
Komatsu S; Hara N; Ishizaki F; Nishiyama T; Takizawa I; Isahaya E; Kawasaki T; Takahashi K
Prostate; 2012 Aug; 72(11):1207-13. PubMed ID: 22213519
[TBL] [Abstract][Full Text] [Related]
37. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
38. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
Foulkes SJ; Daly RM; Fraser SF
Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
McKay RR; Zurita AJ; Werner L; Bruce JY; Carducci MA; Stein MN; Heath EI; Hussain A; Tran HT; Sweeney CJ; Ross RW; Kantoff PW; Slovin SF; Taplin ME
J Clin Oncol; 2016 Jun; 34(16):1913-20. PubMed ID: 27044933
[TBL] [Abstract][Full Text] [Related]
40. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
